sur Zomedica Corp. (NASDAQ:ZOM)
Zomedica Secures License Agreement with Cresilon Inc. for Vetigel® Distribution
Zomedica Corp., a veterinary health company, has announced a new license and supply agreement with Cresilon Inc. The agreement grants Zomedica the rights to market and sell the plant-based Vetigel® hemostatic gel in the U.S., and non-exclusively abroad. Zomedica will handle U.S. distribution while collaborating with Cresilon for international operations.
Vetigel® rapidly stops bleeding, making it valuable in various veterinary procedures. Clinical studies endorse its effectiveness in reducing surgical bleeding and time. Key applications include surgeries, dental procedures, emergency care, and liver biopsies.
Zomedica aims to enhance veterinary procedural efficiency, patient outcomes, and workflow through this partnership, extending its innovative solutions for animal health care. Cresilon's CEO, Joe Landolina, emphasizes the synergy between their revolutionary product and Zomedica's established market presence.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Zomedica Corp.